NICE issues final word on Celgene, J&J meds; Meda share price puts M&A at a premium;

@FiercePharma: DoJ subpoenas AZ, Medco about four meds. Story | Follow @FiercePharma

> The U.K.'s cost-effectiveness watchdog issued final guidance on multiple myeloma drugs, recommending Celgene's thalidomide for first-line treatment and Johnson & Johnson's Velcade for those who can't take the Celgene med. Piece

> Investors bidding up shares in Meda, the Swedish drugmaker said to be targeted by Valeant Pharmaceuticals for a takeover, may price the company out of the market. Report

> India's Dr Reddy's Laboratories launched its version of Eli Lilly's cancer drug Gemzar in the U.S. News

> Walgreen agreed to pay $140,000 to resolve state and federal claims that it defrauded Medicare and Medicaid by billing multiple times for prescription drugs. News

> The U.S. government will be paying half the nation's healthcare bill by 2020, four percentage points higher than the share in 2010, according to a Health Affairs study. Report

> Pharma wholesaler AmerisourceBergen raised its earnings outlook for the second time this year while posting Q2 profits that beat analyst estimates. Item

> India's Cadila Healthcare bought the German animal health company Bremer Pharma to expand its veterinary drugs business. Story

Biotech News

@FierceBiotech: FDA cites "corrupt" CRO for widespread falsification. News | Follow @FierceBiotech

@JohnCFierce: BMS R&D expenses up 12% in Q2, to $923M; won't be any complaints on that score with net sales rising. | Follow @JohnCFierce

@RyanMFierce: You might have seen this before, Broad Inst. CIO presents a case for injecting video game elements into biotech R&D: Item | Follow @RyanMFierce

@MaureenFierce: E&Y: Biotech jobs on the rise in US, but pressures on business model have increased to extraordinary levels. Report | Follow @MaureenFierce

> Baxter sets up $200M venture arm for early-stage investments. News

> GSK chief sees big shakeout following R&D shutdown. More

> Sanofi lines up a growing slate of late stage drug prospects. Article

> Flush with cash, UK biotech preps new discovery in Oxford. Story

Manufacturing News

> Indianapolis strengthens hold as cold chain hub. Item

> UN conference names Catalent top CMO. Piece

> GSK adds consumer savvy to procurment role. Article

> Russia plots API production conquest. Report

> DB Schenker rolls out RFID temp-monitoring service. Story

> Millipore: single-use plus lean cuts time and materials. News

Vaccine News

> Orelli: BioSante melanoma deal could be better. News

> Sanofi taps Leukocare for vaccine stabilization. Story

> Collins: Universal flu vax will be achieved in 5 years. More

> CEVEC raises $8.5M to commercialize protein, vaccine platform. Article

> Chicken pox vaccine reduces deaths. Report

And Finally... Depression study proves money doesn't make people happy. Report

Suggested Articles

It’s been a rocky road for BMS’ immuno-oncology duo in previously untreated lung cancer, but a new addition to the regimen might hold the ticket.

Novartis’ Zolgensma launch has been anything but boring: First a record price, then a data scandal and now a manufacturing-related delay in Europe.

As CEO Paul Hudson focuses Sanofi's R&D program on immuno-oncology and gene therapies, Sanofi is readying a vaccine plant to make viral vectors.